Tag Archives: RESI

Meet The RESI San Francisco Innovation Challenge Finalists

21 Dec

By Chris Cummings, Senior Marketing Manager, LSN

Happy Holidays! With just under 3 weeks until the 4th annual RESI San Francisco, LSN is proud to announce this year’s crop of innovative new life science companies participating in the RESI Innovation Challenge.

The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants are vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

Previous Innovation Challenge participants have proven to be successful entrepreneurs; we have seen as many as 50% of companies in a Challenge receive funding within one year of the conference. Top competitors are able to find a balance between utilizing both the structure of RESI’s partnering system, and the ad-hoc nature of the Innovation Challenge.

On January 9th, RESI SF’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

Therapeutic

Medtech Device

Diagnostic

Healthcare IT

Big Pharma Firms Head Upstream For New Pipeline Assets – Learn Their Strategies at RESI

21 Dec

By Lucy Parkinson, Director of Research, LSN

Major pharma firms are increasingly looking to startups to supply new assets for their pipelines, and LSN’s research has found that many are interested in inking deals at the earliest stages of drug development. Going into 2017, we found that a plurality of pharma deals announced in the previous year concerned preclinical assets.

Due to RESI’s focus on early stage life science companies, the vent has become known as a venue for top pharma firms to uncover new therapeutic opportunities. At RESI San Francisco, the panel on Big Pharma will provide an opportunity to hear straight from five experienced scouts on what they’re looking for, how they make deals and what makes a pharma partnership work.

Moderated by Chris Haskell, VP, Head of West Coast Innovation Center, Bayer Healthcare, the panelists are:

  • Kevin Lynch, Vice President, Search & Evaluation, AbbVie
  • Chris Sheldon, Head, Oncology Search & Evaluation, AstraZeneca
  • Lesley Stolz, Head, JLABS California, Johnson & Johnson Innovation
  • Chris DeRespino, Director Transactions, Amgen

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

21 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

Partnering: Transitioning Conferences from Information-Centric to Relationship-Centric

14 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation’s Redefining Early Stage Investments (RESI) conference is a partnering event that requires high touch on both the buy side (investors and pharma) and sell side (startup) constituents. To do partnering correctly takes a high human resource allocation; it is expensive to fund, and requires deep curation of a clientele database for each conference iteration. LSN has discovered that our database curation begets savvy list management, which in turn allows us to target constituents and provide them with customer support and training to use the partnering system efficiently. In today’s life science domain, conferences still lead as a place to make new business connections in addition to accessing the latest information on the advances in drugs, devices, diagnostics, and healthcare IT.

Informational-based life science conferences have worked for decades to successfully “break the profitability code”. Breaking the code means finding the precise point between internal resource output and maximum revenue gain, and balancing on it. The irony here is that if the conferences wish to be part of the industry’s new trend of relationship-based conferences with a strong partnering component, they will have to modify their view on resource allocation for partnering at their events. This may seem like a small issue that simply requires dedicating more resources to partnering, which causes a hit to the bottom line. However, it is actually a huge core issue that exposes an inherent dichotomy that must be traversed, or we will see a upheaval in the traditional conference market.

A lot of the information-based, super technical, scientific conferences that cater to academia and very early stage discoveries have found themselves in the crosshairs of big pharma and other large partners who are moving upstream to find technology that isn’t already identified and partnered up. This is another reason why these early stage scientific conferences are now in need of a partnering component, which will require higher capital spend and higher human resources to implement. This epiphany will go against the basic grain of the business philosophy of most of the conference providers. I will posit that if they don’t get partnering right, they will become vulnerable as there is a distinct and growing need from both buyers and sellers to build business connections at these conferences. The question is, can the conference providers change the lens on how they value their conferences?

The conference folks I talk to seem unconvinced that you really need a partnering effort that goes beyond a basic software application and a dedicated space at their venues. Indeed, it seems as if they are still trying to talk themselves into supporting partnering at all! Is this a fatal flaw?

Based on the 5 years of experience that I have garnered in the partnering conference marketplace, I will provide some of my insights. Great partnering is very hard to get right, it’s resource intensive and it is “high touch”. You do successful partnering by creating a consistent dialogue with your constituents. This entails focused marketing via newsletters promos, emails and phone canvassing. You need dedicated staff who reach out (yes, talk with!) and understand both the buy-side and sell-side needs of the clients. The staff’s job is to talk to the clients and understand their needs and keep a record of what the client needs, what technology they are interested in and who they are seeking to meet. If you initiate this compelling dialogue, it soon turns into a relationship, and having a direct relationship with your clients is the holy grail.

I also question whether the conference providers want great partnering or “me too” partnering? LSN’s style of interactive dialogue and relationship building through business development is very different than that of info-based conference organizations. LSN’s thesis is that we are NOT a conference company; we are a buyer seller matching platform with a conference, and that’s what gives RESI’s partnering platform its incredible power to forge new connections.

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

14 Dec

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

RESI @ JPM Partnering Launches Monday – See Who’s Attending

7 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wpThe annual JP Morgan healthcare week will soon be upon us and we’re excited to be bringing the RESI conference back to the Bay for a high energy day of partnering, panels and networking. The RESI conference always hosts a wide variety of investment firms, strategic partners and startups, but each year’s San Francisco event is unmatched in the volume and diversity of global players in the mix.

On the investor/strategic partner side, you’ll find everyone from angel groups, venture philanthropy and endowments, venture capital and private equity, family offices, mid-size and big pharma. As for startups, RESI accommodates biotech/pharma (therapeutics), medtech (devices and diagnostics) and healthcare IT/digital health. Have a look at the some of the folks you can meet.

Confirmed Investors and Strategic Partners

Click to See Full List…

Confirmed Companies

Click to See Full List…

Healthcare IT Investors Explore Their Strategies at RESI

7 Dec

By Lucy Parkinson, Director of Research, LSN

The healthcare conference week we all know as JPM began as a gathering for executives in the biotech, pharma and medical technology industries, but the rapidly expanding digital health industry is becoming increasingly a part of the annual San Francisco hubbub. We’ve seen that growth firsthand over the last 3 years of RESI San Francisco events. It’s a sector that investors approach from a diverse range of directions; some funds that previously focused on biotech have broadened into digital health, while traditional technology investors are getting to grips with the healthcare industry. Additionally, many large health systems or payers are looking to digital investments to strategically benefit their business. These investors each bring a unique expertise and perspective to their digital health investment mandates.

On January 9th, five experts in the space will share their strategic insights and advice with entrepreneurs at RESI San Francisco’s Healthcare IT panel. The participants are:

  • Rich Simoni, Managing Partner, Asset Management Ventures
  • Taha Jangda, Partner, HealthX Ventures
  • Brent Stackhouse, Vice President, Mount Sinai Ventures
  • Eric Louie, Chief Medical Officer, Healthbox Global Partners
  • Dennis Depenbusch, Director, New Ventures Initiative, Blue Cross Blue Shield of Kansas